A recent study indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional lifestyle programs.
Published data in a major medical journal shows that while overweight people frequently drop substantial amounts of their body weight while on the medication, the weight is regained at an average rate of nearly a kilo each month once they quit.
"People buying such medications should be cognizant of the potential of fast rebound weight gain when the therapy ends," cautioned lead investigator Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment weight within about 18 months.
Analyzing Approaches
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the effects of GLP-1 agonists with conventional dieting.
The team point out that individuals who lose weight through diet and exercise typically see a more gradual creep back—around 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Experts propose the way of the injections is key to understanding the amplified weight return.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.
"Stopping of this GLP-1 'fix' leads to appetite is uncontrolled, making binge eating a significant risk."
A Chronic Condition?
Medical guidelines recommend the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians say that, considering the significant potential of relapse, the therapy is often life-long.
This opinion is supported by drug manufacturers, who note that the results "emphasize the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Experiences
Individuals who have come off the medication report a intense return of appetite.
"I experienced a trigger that goes on and you're instantly starving," said one woman.
The struggle is exacerbated if users have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Interest
Recent estimates suggest that millions of adults in the UK have used these injections in the past year, with interest being substantial.
- Adoption is greater among women compared to males.
- The middle-aged demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a magic fix and long-term success likely depends on ongoing behavioural changes.
